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Introduction
Tuberculous (TB) is one of the long-known 
diseases and is still the leading cause of death in the world. 
The prevalence of TB in Indonesia and other developing 
countries is quite high. In 2006, new cases in Indonesia 
amounted to more than 600,000 and most of them were 
suffered by people in productive age (15–55 years).
About 20% of infections with pulmonary TB will 
spread out of the lungs (extrapulmonary TB). Eleven 
percent of extrapulmonary TB is osteoarticular TB, and 
nearly half of patients suffer from spinal TB infection. 
Half have lesions in the spine with neurological deficits 
of 10–45% of sufferers.
Spondylitis TB (ST) is an infection of the spine 
caused by Mycobacterium tuberculosis [1], [2], [3] ST 
results in damage to the body in the form of a defect that 
causes spinal instability and disruption of surrounding 
structures [1], [3] The occurrence of infection in ST can 
originate from primary infection [2], [4] bacteria directly 
infect the corpus, or secondary infections [4], namely, 
bacteria spread hematogenously or lymphogenously 
from the location of the primary disease to the spinal 
cord [2]. Infections that occur in ST are generally 
secondary infections of the lungs, but in some cases 
are primary infections. Pro-inflammatory and anti-
inflammatory cytokines play an important role in the 
development and control of M. tuberculosis infection [5]. 
It has been demonstrated that cytokine profiles will differ 
in each degree of disease [1], [5]. Several cytokines 
have been known to be biomarkers of disease activity 
in TB infections. Matrix metalloproteinase (MMP) is 
a zinc-dependent protease, which plays a role in the 
process of degradation of the extracellular matrix and 
modulates the inflammatory response by facilitating 
and inhibiting different cytokines [6], [7].
In determining the form of treatment for ST, it 
is generally divided into two groups of patients, namely, 
groups of patients accompanied by complications in 
the way of neurological disorders and groups that are 
not accompanied by neurological disorders. In patients 
without neurological complications, medical treatment 
is the primary choice in treatment, and surgical 
treatment is only needed in some special cases. 
However, in patients are accompanied by neurological 
complications, the combination of medical treatment 
and surgical management is the most appropriate 
treatment.
Abstract
AIM: We aimed to evaluate and compare the expression of MMP-9 in TB spondylitis using serum levels in the blood 
of patients suffering from TB spondylitis and compared to the control group; in this case, the control group in this 
study was patients with degenerative diseases of the spine.
METHODS: Fourteen subjects were divided into two groups, with seven subjects of spondylitis tuberculous (TB) 
(ST) and seven subjects of degenerative spine disease (DSD) in the period from December 2017 to November 2018 
who were included in the inclusion criteria included in this study and blood sampling was taken for the examination 
of serum matrix metalloproteinase-9 (MMP-9) levels. 
RESULTS: There were significant differences in serum MMP-9 levels between ST and DSDs with a significance 
value of 0.002 (p < 0.05) with low serum MMP-9 levels in the ST study group 1857.14 ± 377.96 and mean in the 
control group 857.14 ± 243.97. There were significant differences in serum MMP-9 levels between ST and DSDs with 
a significance value of 0.002 (p < 0.05) with low serum MMP-9 levels in the ST study group 1857.14 ± 377.96 and 
mean in the control group 857.14 ± 243.97. 
CONCLUSION: Patients suffering from ST have higher serum MMP-9 levels than patients with DSD, although 
MMP-9 is not a specific marker examination for ST, the results of this study can be suggestive into that can help to 
evaluate enzyme activity in patients with ST disease.
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MMP is a zinc-dependent proteinase that has 
an important role in the degradation and rotation of the 
extracellular matrix [3]. Since it was first reported, 24 
members of MMP have been identified with specificity 
and function of overlapping substrates. Following each 
substrate and function specification, MMP is divided into 
six classes: Stromelysins, collagenases, matrilysins, 
gelatinases, membrane-type MMPs, and others.
Two gelatinases, MMP-2 and MMP-9 can reduce 
original type IV collagen and denaturation of type I collagen 
(gelatin). Both circulation and resident inflammatory 
cells can synthesize MMP-9. Experimental studies have 
provided evidence that MMP-9 levels were significantly 
higher in bronchoalveolar fluid patients with cavitary active 
TB, and lung extracts of mice infected with M. tuberculosis, 
compared to the control group. An increased significance 
of MMP-9 was also observed in TB cerebrospinal fluid 
(CSF) meningitis patients and also compared with people 
suffering from viral meningitis, where usually these 
enzymes are generally not found in CSF.
Many previous studies have shown that 
M. tuberculosis can stimulate MMP-9 expression in 
the lungs of infected organisms, but no studies have 
examined how the expression of MMP-9 in TB spondylitis 
when compared to the control group. Therefore, 
researchers are interested in trying to evaluate and 
compare the expression of MMP-9 in TB spondylitis 
using serum levels in the blood of patients suffering 
from TB spondylitis and compared to the control group; 
in this case, the control group in this study was patients 
with degenerative diseases of the spine.
Methods
This cross-sectional study was conducted at 
the Faculty of Medicine, Universitas Sumatra Utara/
Haji Adam Malik Hospital, North Sumatra, Indonesia, 
for 11 months from December 2017 to November 2018 
by taking patient data and examining serum values of 
MMP-9, 14 subjects met the inclusion criteria.
Patients met the inclusion criteria recorded age, 
sex, and blood tests to determine serum MMP-9 levels.
The study sample was divided consecutively 
with equal numbers into two groups, namely: ST, and 
degenerative spine disease (DSD). Patients were 
obtained from outpatient or inpatient care diagnosed 
with ST and DSD. Patients who were included in the 
inclusion criteria were taken for blood sampling to 
examine levels of MMP-9.
The MMP-9 examination in this study used MMP-9 
ELISA Kit from fine test with the catalog number ERB0080, 
size 48T/96T and reactivity to humans. The scale value 
used is 3.125–200 ng/ml with sensitivity: <1.875 ng/ml. 
The application of the dosage is a quantitative detection 
of MMP-9 in serum, plasma, tissue homogenates, and 
other biological fluids. The differences in serum MMP-9 
values in ST with the degenerative disease in the spine 
were analyzed using the Mann–Whitney test because the 
data obtained were abnormally distributed. All statistical 
calculations are carried out using a computer-based 
statistical program. The study was approved by the Health 
Research Ethics Committee of the Medical Faculty of the 
University of North Sumatra/Haji Adam Malik Hospital, 
and informed consent was obtained from all subjects.
Results
Before discussing the results of the study, 
because this study had no references, it was conducted 
with a small-scale preliminary study using ten balanced 
numbers of research subjects (five subjects with ST, 
and five subjects with DSD) with women as many as six 
people (60%) and men as many as four people (40%), 
with a mean and standard deviation of 41.6 ± 18.8 
years, while the mean of subjects with ST 1800 ± 447.2 
and mean DSD 800 ± 273.8 (Table 1).
Table 1: Preliminary study distribution
Variable Disease
ST DSD
Gender M/F 1/4 3/2
MMP-9 (nm/ml) 1800 ± 447.2 800 ± 273.8
Mean age 41.6 ± 18.8
ST: Spondylitis tuberculous, DSD: Degenerative spine disease, n: Subject. MMP-9: Matrix 
metalloproteinase-9.
A total of 14 subjects were studied until 
the final analysis. Data retrieval and examination of 
serum MMP-9 values in ST and DSD were carried out 
in stages with the initial phase of selecting samples 
of subjects included in the inclusion criteria. Seven 
subjects with diagnosed ST, seven subjects with 
diagnoses of DSD, eight women (57.1%), and six 
men (42.9%), 13 years old are the youngest research 
subjects and 73 years old oldest subjects with mean 
and standard deviations amounting to 44.79 ± 
16.98 years. From the results of the analysis, it was 
found that the mean and standard deviation of serum 
ST MMP-9 values was 1857.14 ± 377.96 while the 
mean and standard deviation of serum DSD levels of 
MMP-9 was 857.14 ± 243.97 (Table 2).
Table 2: Study subject distribution
Variable Disease
ST MMP-9 (nm/ml) DSD MMP-9 (nm/ml)
Patient
1 2000 1000
2 1000 1000
3 2000 500
4 2000 500
5 2000 1000
6 2000 1000
7 2000 1000
Mean MMP-9 (nm/ml) ± SD 1857.14 ± 377.96 857.14 ± 243.97
p-value 0.002
Youngest age 13 year old 43 year old
Oldest age 62 year old 73 year old
TB drug consumption 9.14 ± 5.29 weeks 0
ST: Spondylitis tuberculous, DSD: Degenerative spine disease, n: Subject. MMP-9: Matrix 
metalloproteinase-9, TB: Tuberculous.
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From the results of the statistical analysis of 
the comparison of serum MMP-9 values in ST with 
DSD, the results were significant that the serum MMP-9 
values were higher and this was indicated by p = 0.002 
(p <0.05).
Discussion
Pott’s disease is the most common spinal 
granulomatous bacterial infection and is the most 
frequent bone TB [5]. The occurrence of infection in ST 
can originate from primary infection [2], [4], i.e. bacteria 
directly infect the corpus, or secondary infections [6], 
namely, bacteria spread hematogenously or lymphogenic 
from the location of the primary infection to the spinal cord 
[2]. Infections that occur in ST are generally secondary 
infections of the lungs, but in some cases are primary 
infections. Pro-inflammatory and anti-inflammatory 
cytokines play an important role in the development 
and control of M. tuberculosis infection [5]. It has been 
demonstrated that cytokine profiles will differ in each 
degree of [1], [4] Several cytokines have been known to 
be biomarkers of disease activity in TB infections. MMP 
is a zinc-dependent protease, which plays a role in the 
process of degradation of the extracellular matrix and 
modulates the inflammatory response by facilitating and 
inhibiting different cytokines [6].
Two gelatinases, MMP-2 and MMP-9 have 
the ability to reduce original type IV collagen and 
denaturation of type I collagen (gelatin). Both circulation 
and resident inflammatory cells have the capacity to 
synthesize MMP-9. Experimental studies have provided 
evidence that MMP-9 levels were significantly higher in 
bronchoalveolar fluid patients with cavitary active TB, 
and lung extracts of mice infected with M. tuberculosis, 
compared to the control group.
In a study conducted by Hrabec et al., 2002 [8], 
it was found that serum MMP-9 levels in patients with 
active pulmonary TB had significantly higher levels of 
the control group with mean MMP-9 levels in the group 
with pulmonary TB 1.23 ± 0.43 µU/µL, while the mean 
MMP-9 level in the control group was 0.37 ± 0.10 µU/µL 
and this result was in accordance with the function 
of MMP-9 which could induce enzymes produced by 
mononuclear phagocytes and stimulated neutrophils. 
This finding is in accordance with the study conducted 
that there was a significant difference in MMP-9 levels 
in patients with ST with a control group used in this 
group with subjects with DSD with mean ST patients 
1857.14 ± 377.96 while the mean in patients with DSD 
857.14 ± 243.97 with p = 0.002 (p <0.05), but in this 
study, there was no comparison of the ratio of white 
blood cell levels in the two study groups as did the 
research conducted by Hrabec et al., 2002, with this 
study obtained MMP-9 rate with an increase in white 
blood cells was significantly higher in the study group 
with pulmonary TB 0.150 ± 0.054 mU/ml/L while in the 
control group 0.059 ± 0.023 mU/ml/L. In this study, 
no correlation was found between the duration of 
consumption of anti-TB drug and an increase in serum 
MMP-9 levels (p > 0.05) with an average use for TB 
medicines 9.14 ± 5.29 weeks, although this was not a 
primary goal in this study, need to be reviewed, because 
this assessment only uses seven research subjects [9], 
[10], [11].
Conclusion
From the results of the comparison of serum 
MMP-9 values in ST with DSD, it was found that the 
serum MMP-9 values in ST gave higher results so that 
MMP-9 examination could be used as a barometer for 
the diagnosis of ST.
Further studies are needed to find out whether 
the increase in serum MMP-9 levels in TB spondylitis 
is also accompanied by an increase in the ratio of 
white blood cells and further studies are needed to 
determine whether an increase in serum MMP-9 
levels can also be influenced by the duration of use of 
anti-TB drugs.
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